Financial obligations of the Institution Sample Clauses

Financial obligations of the Institution. The payments specified in Section 5(a) above shall constitute the Institution’s, Investigator’s and his/her Team’s sole remuneration in connection with the Trial. In the event that Biogen has not given its prior express written approval regarding any costs or expenses, the Institution shall be responsible for all costs and expenses arising from the conduct of the Trial, including but not limited to, pharmacy fees and laboratory tests.
Sample 1See All (6)
AutoNDA by SimpleDocs
Financial obligations of the Institution. The payments specified in Section5(a) above shall constitute the Institution’s sole remuneration in connection with the Trial. In the event that Biogen has not given its prior express written approval regarding any costs or expenses, the Institution shall be responsible for all costs and expenses arising from the conduct of the Trial, including but not limited to, the remuneration of the Investigator and all Staff members, pharmacy fees and laboratory tests, if applicable. With regard to this Study, Biogen and CRO shall not enter into any separate agreements with the Investigator nor any member of the Staff. (b) Finanční závazky Zdravotnického zařízení. Platby uvedené v čl. 5(a) výše budou představovat jedinou odměnu náležející Zdravotnickému zařízení v souvislosti s Klinickým hodnocením. V případě, že společnost Biogen předem výslovně a písemnou formou neschválila jakékoliv náklady a výdaje, bude Zdravotnické zařízení odpovědné za úhradu veškerých nákladů a výdajů vyplývajících z provádění Klinického hodnocení, zejména za výplatu odměny všem členům Personálu, lékárnické poplatky a laboratorní testy. Biogen ani CRO neuzavřou žádnou separátní smlouvu se Zkoušejícím ani s žádným členem Personálu v souvislosti s touto Studií.
Sample 1
Financial obligations of the Institution. The payments specified in Section 5(a) above shall constitute the Institution’s sole remuneration in connection with the Trial. In the event that Biogen has not given its prior express written approval regarding any costs or expenses, the Institution shall be responsible for all costs and expenses arising from the conduct of the Trial, including but not limited to, the remuneration of all Staff members, pharmacy fees, radiology fees and laboratory tests. Biogen shall enter into separate agreements with some members of Staff regarding activities required for this Trial beyond the scope of activities performed by the Institution hereunder. Such agreements shall, among other things, provide for compensations for the performance of abovementioned activities.
Sample 1
Financial obligations of the Institution. The payments specified in Section 5(a) above shall constitute the Institution’s sole remuneration in connection with the Trial. In the event that Biogen has not given its prior express written approval regarding any costs or expenses, the Institution shall be responsible for all costs and expenses arising from the conduct of the Trial, including but not limited to, the remuneration of the Investigator and all Staff members, (except the extra Staff member(s) appointed under Section 3(b) who shall be paid by the site management entity). Biogen shall enter into separate agreements with some members of Staff regarding activities required for this Trial beyond the scope of activities performed by the Institution hereunder. Such agreements shall, among other things, provide for compensations for the performance of abovementioned activities.
Sample 1
Financial obligations of the Institution. The payments specified in Section5(a) above shall constitute the Institution’s, Investigator’s and his/her Team’s sole remuneration in connection with the Trial. In the event that Biogen has not given its prior express written approval regarding any costs or expenses, the Institution shall be responsible for all costs and expenses arising from the conduct of the Trial, including but not limited to, pharmacy fees and laboratory tests. (b) Finanční závazky Zdravotnického zařízení. Platby uvedené v čl. 5(a) výše budou představovat jedinou odměnu náležející Zdravotnickému zařízení, Zkoušejícímu a jeho týmu v souvislosti s Klinickým hodnocením. V případě, že společnost Biogen předem výslovně a písemnou formou neschválila jakékoliv náklady a výdaje, bude Zdravotnické zařízení odpovědné za úhradu veškerých nákladů a výdajů vyplývajících z provádění Klinického hodnocení, zejména za výplatu, lékárnických poplatků a laboratorních testů. (c) Each party represents and warrants to the others that the payment of the fees related to the conduct of the Trial (including payments to subcontractors, consultants, or other agents working on behalf of the Institution/the Investigator or as part of the Institution’s and/or Investigator’s services to Biogen, as applicable) (i) represents the fair market value for the conduct of the Trial, (ii) has not been determined in any manner that takes into account the volume or value of any referrals, reimbursements or business between the Institution and/or the Investigator and Biogen and/or CRO, and (iii) is not offered or provided, in whole or in part, with the intent of, directly or indirectly, implicitly or explicitly, influencing or encouraging the recipient to purchase, prescribe, refer, sell, arrange for the purchase or sale, or recommend favorable formulary placement of a Biogen product or as a reward for past behavior. (c) Xxxxx xxxxxxx xxxxxx xxxxxxxxxx x xxxxxxxx xxxxxxxx, xx platba poplatků souvisejících s prováděním klinického hodnocení (včetně plateb subdodavatelům, konzultantům a jiným zástupcům pracujícím jménem zdravotnického zařízení/zkoušejícího nebo jako součást služeb zdravotnického zařízení/zkoušejícího pro společnost Biogen, dle situace) (i) představuje spravedlivou tržní hodnotu za provádění klinického hodnocení, (ii) nebyla stanovena žádným způsobem, který bere v úvahu objem nebo hodnotu jakýchkoliv doporučení, úhrad nebo obchodů mezi zdravotnickým zařízením a/nebo zkoušejícím a společností Biogen a/nebo CRO a (ii...
Sample 1
Financial obligations of the Institution. The payments indicated in this Agreement shall constitute the Institution’s sole remuneration for the conduct of the Study, including the storage and administering the Product and the Material. It is the Institution’s responsibility to meet its own fiscal obligations in relation to these payments. In the event that Sponsor or TFS has not given its prior express written approval regarding any costs or expenses, the Institution shall be responsible for all costs and expenses arising from the conduct of the Study. 5.3. Finanční závazky zdravotnického zařízení. Platby uvedené v této smlouvě tvoří celou odměnu zdravotnického zařízení za provádění klinického hodnocení, včetně skladování a podávání přípravku a materiálu. Zdravotnické zařízení má povinnost splnit své vlastní finanční závazky v souvislosti s těmito platbami. Pokud zadavatel nebo TFS nedají předem výslovný písemný souhlas ohledně jakýchkoliv nákladů nebo výdajů, zdravotnické zařízení uhradí všechny náklady a výdaje vznikající z provádění klinického hodnocení. Each party represents and warrants to the others that the payment of the fees related to the conduct of the Study (including payments to subcontractors, consultants, or other agents working on behalf of the Institution or as part of the Institution’s services to Sponsor, as applicable) (i) represents the fair market value for the conduct of the Study, (ii) has not been determined in any manner that takes into account the volume or value of any referrals, reimbursements or business between the Institution and/or the Investigator and Sponsor, and (iii) is not offered or provided, in whole or in part, with the intent of, Xxxxx xxxxxx xx xxxxxxxx x xxxx xxxxxxxx xxxxxxx xx to, že poplatky související s realizací klinického hodnocení (včetně plateb subdodavatelům, konzultantům nebo jiným zástupcům působícím jménem zdravotnického zařízení , případně jako poskytovatel služeb zdravotnického zařízení zadavateli, v příslušných případech (i) představují spravedlivou tržní hodnotu za realizaci klinického hodnocení, (ii) nebyly určeny způsobem, který zohledňuje objem nebo hodnotu jakýchkoli oficiálních doporučení, úhrad nebo obchodů mezi institucí a zkoušejícím a directly or indirectly, implicitly or zadavatelem a (iii) není nabízena explicitly, influencing or encouraging ani poskytována, částečně ani jako the recipient to purchase, prescribe, celek, s úmyslem přímo nebo refer, sell, arrange for the purchase nepřímo, implicitně nebo explicitně or sale, or r...
Sample 1

Related to Financial obligations of the Institution

  • Additional Obligations of the Company The Company shall:

  • OBLIGATIONS OF THE INVESTOR a. The Company shall notify the Investor in writing of the information the Company reasonably requires from the Investor in connection with any registration statement hereunder. The Investor shall furnish to the Company such information regarding itself, the Registrable Securities held by it and the intended method of disposition of the Registrable Securities held by it as shall be reasonably required to effect the registration of such Registrable Securities and shall execute such documents in connection with such registration as the Company may reasonably request.

  • Obligations of the Investors In connection with the registration of the Registrable Securities, the Investors shall have the following obligations:

  • Obligations of the Investment Adviser a. The Investment Adviser shall provide (or cause the Trust's custodian to provide) timely information to the Subadviser regarding such matters as the composition of assets in the Fund, cash requirements and cash available for investment in the Fund, and all other information as may be reasonably necessary for the Subadviser to perform its responsibilities hereunder.

  • FINANCIAL OBLIGATIONS There will be no transfer of funds between the Parties under this Agreement and each Party will fund its own participation. All activities under or pursuant to this Agreement are subject to the availability of funds, and no provision of this Agreement shall be interpreted to require obligation or payment of funds in violation of the Anti-Deficiency Act, (31 U.S.C. § 1341).

  • Obligations of the Sponsor The Sponsor agrees to provide the Asset Representations Reviewer with the following: • Reasonable access to the Sponsor; • Complete AUPs; • Required Documents; and • Other related information reasonably requested by the Asset Representations Reviewer to perform the Services hereunder.

  • CONDITIONS OF THE OBLIGATIONS OF THE COMPANY The obligations of the Company to sell and deliver the portion of the Shares required to be delivered as and when specified in this Agreement are subject to the conditions that at the Closing Date or the Option Closing Date, as the case may be, no stop order suspending the effectiveness of the Registration Statement shall have been issued and in effect or proceedings therefor initiated or threatened.

  • Obligations of the Company Whenever required under this Section 2 to effect the registration of any Registrable Securities, the Company shall, as expeditiously as reasonably possible:

  • Further Obligations of the Company Whenever the Company is required hereunder to register any Registrable Securities, it agrees that it shall also do the following:

  • Obligations of the Seller The obligations of the Seller under this Agreement will not be affected by reason of any invalidity, illegality or irregularity of the 2016-A Exchange Note or any 2016-A Lease or 2016-A Vehicle allocated to the 2016-A Reference Pool.

Time is Money Join Law Insider Premium to draft better contracts faster.